ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0049

Inflammatory Priming by Anti-MAA Antibodies in Rheumatoid Arthritis

Marcelo Afonso1, Jitong Sun1, Koji Sakuraba1, Alexandra Circiumaru2, Denis Lagutkin1, Masa Filipovic1, Anca Catrina1, Caroline Grönwall1, Aase Hensvold1 and Bence Réthi1, 1Karolinska Institutet, Stockholm, Sweden, 2Division for Rheumatology, Karolinska Institutet; Center for Rheumatology, Academic Specialist Center, Stockholm region, Stockholm, Sweden

Meeting: ACR Convergence 2024

Keywords: Autoantibody(ies), Inflammation, macrophages, rheumatoid arthritis, risk factors

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 16, 2024

Title: RA – Etiology & Pathogenesis Poster

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: We have previously shown that autoantibodies targeting malondialdehyde-acetaldehyde protein adducts (anti-MAA) in rheumatoid arthritis (RA) patients boosted osteoclast differentiation and induced bone erosion in mice (1). Anti-MAA IgG levels are increased in certain autoimmune diseases suggesting a link between inflammation and MAA autoimmunity (2), however, the cause and consequence in this relationship have not been investigated. IgG anti-MAA responses could be triggered by the oxidative stress in an inflammatory milieu, but these antibodies might also be pathogenic mediators driving certain inflammatory processes. Here we studied the effects of IgG anti-MAA on inflammation and, more specifically, on macrophage functions.   

Methods: We measured serum anti-MAA IgG levels in individuals at risk of RA using ELISA, and analyzed a potential link to disease progression and to circulating inflammatory mediators, monitored by Olink Proximity Extension Assay. We tested the effects of patient-derived anti-MAA antibodies on macrophage gene expression and cytokine profile and on joint inflammation in mice.

Results: A set of circulating immune mediators, CCL19, sIL-15Rα, CD5, CXCL10 and TNFRSF9 correlated with anti-MAA levels in a period immediately preceding arthritis onset (6 month in median), whereas 15 (out of the detected 78) immune mediators correlated with anti-MAA at disease onset. A low number of transient associations have been observed in individuals not yet progressing to RA. In mechanistic experiments, we detected a profound reprogramming of gene expressions and the production of chemokines, such as CCL22 and CCL24 in anti-MAA exposed macrophages. Moreover, anti-MAA pretreatment promoted a more inflammatory cytokine profile upon TLR activation. Although anti-MAA are multi-reactive towards different MAA-modified proteins, we observed a prominent clonal diversity in inducing macrophage activation. Anti-MAA antibodies had no arthritogenic effect in mice but altered gene expressions in the joints following LPS stimulation, affecting a set of genes encoding cytokines and growth factors.

Conclusion: Certain IgG anti-MAA clones may thus contribute to an inflammatory priming of the joint, and potentially other tissues, prior to the onset of systemic inflammation. FcγR-mediated macrophage pre-activation could play an important role in this effect, by setting the stage for augmented responses to subsequent inflammatory stimuli. The clonal diversity in macrophage modulation suggests on the other hand a high level of patient-to-patient variability in the overall effects of the carried anti-MAA repertoire.

1. Sakuraba et al. J Autoimmun 2022
2. Grönwall et al. J Autoimmun 2017


Disclosures: M. Afonso: None; J. Sun: None; K. Sakuraba: None; A. Circiumaru: None; D. Lagutkin: None; M. Filipovic: None; A. Catrina: None; C. Grönwall: None; A. Hensvold: None; B. Réthi: None.

To cite this abstract in AMA style:

Afonso M, Sun J, Sakuraba K, Circiumaru A, Lagutkin D, Filipovic M, Catrina A, Grönwall C, Hensvold A, Réthi B. Inflammatory Priming by Anti-MAA Antibodies in Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/inflammatory-priming-by-anti-maa-antibodies-in-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/inflammatory-priming-by-anti-maa-antibodies-in-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology